FDA has been approved CAR-T therapy (Clinical trials of chimeric genetically modified T cells for CD19 by Kite Pharma) for diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL), not otherwise specified. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.